2C-T-17

2C-T-17
Clinical data
Other names4-sec-Butylthio-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-sec-butylthiophenethylamine; NIMITZ; Nimitz
Routes of
administration
Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action10–15 hours[1]
Identifiers
  • 2-(4-butan-2-ylsulfanyl-2,5-dimethoxyphenyl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23NO2S
Molar mass269.40 g·mol−1
3D model (JSmol)
  • CC(CC)Sc1cc(OC)c(cc1OC)CCN
  • InChI=1S/C14H23NO2S/c1-5-10(2)18-14-9-12(16-3)11(6-7-15)8-13(14)17-4/h8-10H,5-7,15H2,1-4H3 checkY
  • Key:KSZHVRPGICAZOA-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

2C-T-17, also known as 4-sec-butylthio-2,5-dimethoxyphenethylamine or as Nimitz, is a psychedelic drug of the phenethylamine and 2C families.[1] It is taken orally.[1]

2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991.[2] Shortly after this, Shulgin described 2C-T-17 in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[1]

Use and effects

According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), 2C-T-17's dose range is 60 to 100 mg and its duration is 10 to 15 hours.[1] Its onset is 1 hour and peak effects occurred after 3 hours.[1] 2C-T-17 has been described as a "truly heavy psychedelic" but as producing no psychedelic visuals and very little in the way of perceptual changes.[1] User reports described it as having pronounced psychoactive effects but had difficulty describing exactly what those effects were.[1]

Toxicity

The toxicity of 2C-T-17 is not well-documented. It is much less potent than 2C-T-7, but it may be expected that at very high doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.

Interactions

Pharmacology

Pharmacodynamics

The mechanism of action that produces 2C-T-17's hallucinogenic effects has not been specifically established, however it is most likely to result from action as a serotonin 5-HT2A receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.

Chemistry

2C-T-17 is the 2 carbon homologue of Aleph-17, which has never been synthesized.[1] The full chemical name is 2-[4-(2-butyl thio)-2,5-dimethoxy phenyl]ethanamine.[1] The drug has structural properties similar to drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-8.[1]

History

2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in a journal article in 1991.[2] Shortly thereafter, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[1]

Society and culture

Canada

As of October 31, 2016, 2C-T-17 is a controlled substance (Schedule III) in Canada.[3]

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[4]

United States

2C-T-17 is not illegal, but possession and sales of 2C-T-17 could be prosecuted under the Federal Analog Act in the United States because of its structural similarities to 2C-T-7.

See also

References

  1. ^ a b c d e f g h i j k l m Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  2. ^ a b Shulgin AT, Shulgin A, Jacob P (January 1991). "Central nervous system (CNS) activity of two new psychoactive compounds". Journal of Psychoactive Drugs. 23 (1): 95–96. doi:10.1080/02791072.1991.10472583. eISSN 2159-9777. PMID 1941371. Archived from the original on 2025-07-13.
  3. ^ "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". 4 May 2016.
  4. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.